Hyoid Suspension to the Mandible for the Treatment of Obstructive Sleep Apnea

NCT ID: NCT02738112

Last Updated: 2018-06-27

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 30 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2016-03-31
• Study Completion Date: 2019-06-30

Brief Summary

Hyo-mandibular suspension has been previously studied as a treatment for obstructive sleep apnea (OSA) and has shown to be highly effective.

This is a prospective, multi-center, registry during which 30 subjects with OSA will be considered for hyo-mandubular suspension treatment. After obtaining informed consent and meeting all inclusions and exclusion criteria, subjects will be treated using the Encore System. Subject follow-up with the physician or nurse will occur at one (1) week, one (1) month, three (3) months, and twelve (12) months.

This study will assess the effectiveness of hyoid suspension in reducing the apnea-hypopnea index (AHI), and improving the Epworth Sleepiness Scale (ESS), snoring (VAS) and functional outcome (FOSQ) for the treatment of obstructive sleep apnea (OSA). In addition, the study will evaluate the effect that the change in hyoid position has on the airway anatomy.

Detailed Description

Obstructive sleep apnea (OSA) has become a major heath problem in the United States. With prevalence in middle-aged adults of 2 to 4% of the population, untreated OSA has been implicated in increased risk for cardiovascular disease, including hypertension and heart failure.

The first line and most common treatment for OSA is continuous positive airway pressure (CPAP) treatment, utilized by an estimated 3 million Americans. CPAP is effective in reducing the AHI if used properly. However, the nasal mask required for CPAP during sleep leads to poor acceptance and compliance rates. Published studies on CPAP have shown that only 58 to 80% of patients accept CPAP therapy,, and further 65 to 90% of these patients exhibit long-term compliance with CPAP. Additionally, there are many patients who would choose other therapy besides CPAP.

Patients cite a number of issues with CPAP, namely discomfort and inability to sleep while connected to an air pump. Auto-titrating CPAP, heated and humidified air, and bi-PAP (different pressures on inspiration and expiration) have improved patient compliance, but there remains a significant unmet clinical need.

It is widely accepted that the region behind the tongue is a major site of collapse during obstructive sleep apnea. In fact, there are many surgical procedures performed currently to address tongue base collapse. These include: RF ablation (Somnoplasty) of the tongue base; genioglossus advancement; Medtronic's Repose system for tongue base suspension; hyoid suspension; and maxillomandibular advancement (MMA). The change in airway dimension after MMA surgery on the lateral cephalograph is presented in Figure 1.

One of the principal mechanisms of effect of MMA surgery is to move the base of the tongue and the attached structures forward. Hyo-mandibular suspension has been previously studied as a treatment for OSA and has shown to be highly effective.

This is a prospective, multi-center, registry during which 30 subjects with OSA will be considered for hyo-mandubular suspension treatment. After obtaining informed consent and meeting all inclusions and exclusion criteria, subjects will be treated using the Encore System. Subject follow-up with the physician or nurse will occur at one (1) week, one (1) month, three (3) months, and twelve (12) months.

This study will assess the effectiveness of hyoid suspension in reducing the apnea-hypopnea index (AHI), and improving the Epworth Sleepiness Scale (ESS), snoring (VAS) and functional outcome (FOSQ) for the treatment of obstructive sleep apnea (OSA). In addition, the study will evaluate the effect that the change in hyoid position has on the airway anatomy.

Conditions

Obstructive Sleep Apnea

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Interventions

Encore System

Hyo-mandibular suspension

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Documented diagnosis of moderate or severe obstructive sleep apnea (AHI between 20 and 60/hour) evaluated with a sleep study within 12 months prior to the planned procedure

2. Age ≥ 20 and ≤ 65 years old

3. Body Mass Index (BMI) ≤ 36 (kg/m2)

4. Patient has been offered CPAP and has refused or failed to continue CPAP treatment or is noncompliant with CPAP

5. Significant airway narrowing while mild posterior is pressure applied to hyoid bone

6. Evidence of hypopharyngeal obstruction via pharyngoscopy

7. Signed informed consent to participate in this clinical study

Exclusion Criteria

Patient History

1. Prior OSA surgery (uvulopalatopharyngoplasty [UPPP], tonsillectomy and nasal surgery are acceptable)

2. Active systemic infection

3. Allergy to any medication used during implantation

4. Previous history of neck or upper respiratory tract cancer

5. Radiation therapy to neck or upper respiratory tract

6. Significant dysphagia or speech disorder Anatomical Considerations

1. Identified obvious palatal stenosis 2. Enlarged tonsils (3+) 3. Anatomy unable to accommodate the implant

Other

1. Other medical, social or psychological problems that, in the opinion of the investigator, preclude patient from receiving this treatment, as well as the procedures and evaluations pre- and post-treatment

2. Enrollment in another pharmacological or medical device study that may effect or bias the results of this clinical study

3. Unable and/or not willing to comply with treatment follow-up requirements

4. Pregnancy (Female subjects of childbearing potential must have a negative pregnancy test prior to enrollment.)

5. Lack of insurance coverage for procedure and PSG follow up and unwillingness to self pay

6. Unwilling or unable to give signed informed consent

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Abidin, Michael, M.D.

INDIV

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Michael Abidin, MD

Role: PRINCIPAL_INVESTIGATOR

Private Practice

Locations

Michael Abidin

Alexandria, Virginia, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Dustin A Platter, B.S.

Role: CONTACT

dustin.platter1@gmail.com

301-501-0752

Facility Contacts

Dustin A Platter, BS

Role: primary

dustin.platter1@gmail.com

301-501-0752

Other Identifiers

HS 2016.0

Identifier Type: -

Identifier Source: org_study_id